## 근거표 5; LABA + LAMA vs LAMA

### Result
Number: 572 (Indacaterol + tio), 570 (Tio + placebo)

#### Differences between indacaterol + tio vs. tio +placebo
| Item                              | Indacaterol + tio    | Tio + placebo        |
| :-------------------------------- | :------------------- | :------------------- |
| FEV₁ AUC 5 min~8 h                | 130 mL (90~160)      | 110 mL (80~140)      |
| COPD severity - moderate          | 130 mL (90~160)      | 110 mL (80~140)      |
|             - severe              | 110 mL (80~140)      | 90 mL (50~120)       |
| Smoking status - ex smoker        | 140 mL (110~170)     | 140 mL (100~170)     |
|                 - current smoker  | 90 mL (50~120)       | 100 mL (70~140)      |
| ICS use - non-users               | 140 mL (100~170)     | 90 mL (60~120)       |
|           - users                 | 100 mL (70~140)      | 60 mL (30~90)        |
| Trough FEV₁                       | 90 mL (60~120)       | 80 mL (60~110)       |
| COPD severity - moderate          | 60 mL (30~90)        | 60 mL (20~90)        |
|             - severe              | 80 mL (60~110)       | 60 mL (20~90)        |
| Smoking status - ex smoker        | 60 mL (20~90)        | 90 mL (60~120)       |
|                  - current smoker | 90 mL (60~120)       | 60 mL (30~90)        |
| ICS use - non-users               | 60 mL (30~90)        | 90 mL (60~120)       |
|           - users                 | 60 mL (30~90)        |                      |

### Patient reported symptoms and use of as-needed salbutamol
| Item                                          | Indacaterol + tio | Tio + placebo |
| :-------------------------------------------- | :---------------- | :------------ |
| Change from baseline symptom score (full 24 h)| -2,2 (0,21)       | -1,5 (0,21)   |
| Change from baseline symptom score (day-time) | -1,1 (0,12)       | -0,8 (0,12)   |
| Change from baseline symptom score (night-time)| -1,0 (0,12)       | -0,7 (0,12)   |
| Change from baseline salbutamol use (puff/day)| -2,1 (0,17)       | -1,4 (0,17)   |
| Days during treatment with no salbutamol use (%)| 38,7 (1,94)       | 33,6 (1,92)   |

### Adverse events (%)
| Item                             | Indacaterol + tio | Tio + placebo |
| :------------------------------- | :---------------- | :------------ |
| Cough                            | 9,1               | 4,4           |
| Muscle spasm                     | 0,3               | 1,1           |
| Plasma potassium <3,5 mmol/L     | 1,6               | 1,4           |
| Systolic BP-high                 | 0,7               | 0,4           |
| QTc interval (absolute value)    | 1,8               | 2,6           |

\*post-salbutamol for FEV₁ % and FEV₁/FVC and pre/post salbutamol for reversibility

6) 폐기능이 정상예측치의 60% 미만인 경우 증상 호전, 폐기능과 삶의 질 향상, 급성 악화 감소를 위해 흡입스테로이드 사용을 추가할 수 있다(근거수준: 낮음, 권고강도: 강함).

## 근거표 6; Inhaled corticosteroid
| 연구수 | 연구설계 | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
| :----- | :------- | :---------- | :------- | :------- | :------- | :---------- | :------- |
| 1      | 사후분석 | 없음        | 없음     | 없음     | 없음     | 없음        | 낮음     |

Author/year publication: Multicenter, Christine R Jenkins
Title: Efficacy of salmeterol/fluticasone propionate by GOLD stage of COPD; analysis from the randomized, placebo-controlled TORCH study
Country: 42 countries including Australia, London, USA, and Denmark
Setting/Design: Double-blind, placebo-controlled trial
Time frame: 2 Year (September 2000 and the last in November 2002)
Randomization method: Permuted blocks with stratification according to country and smoking status
Allocation concealment: Yes
Blinding
- Participants: Yes

<PAGE>110